Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 12.13 -7.12% -0.93
ENTA closed down 7.12 percent on Friday, May 17, 2024, on 1.41 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Fell Below 20 DMA Bearish -7.12%
Crossed Above 20 DMA Bullish -9.07%
MACD Bullish Signal Line Cross Bullish -9.07%
Earnings Movers Other -9.07%
Gapped Up Strength -9.07%
Up 3 Days in a Row Strength -9.07%
20 DMA Resistance Bearish -8.38%
NR7 Range Contraction -8.38%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Enanta Pharmaceuticals, Inc. Description

Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Chemical Compounds Infection Medical Research Viruses Hepatitis C Hepatitis C Virus HCV Staphylococcus Aureus Treatment Of Hepatitis Cyclophilin Cyclopropanes Methicillin HCV Infection Pyrrolidines

Is ENTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.245
52 Week Low 8.08
Average Volume 190,388
200-Day Moving Average 12.44
50-Day Moving Average 14.50
20-Day Moving Average 13.24
10-Day Moving Average 13.07
Average True Range 0.82
RSI (14) 37.89
ADX 19.19
+DI 23.68
-DI 37.62
Chandelier Exit (Long, 3 ATRs) 12.92
Chandelier Exit (Short, 3 ATRs) 14.06
Upper Bollinger Bands 14.65
Lower Bollinger Band 11.83
Percent B (%b) 0.11
BandWidth 21.30
MACD Line -0.49
MACD Signal Line -0.44
MACD Histogram -0.0407
Fundamentals Value
Market Cap 256.62 Million
Num Shares 21.2 Million
EPS -6.57
Price-to-Earnings (P/E) Ratio -1.85
Price-to-Sales 3.55
Price-to-Book 1.36
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.57
Resistance 3 (R3) 13.71 13.36 13.33
Resistance 2 (R2) 13.36 13.00 13.30 13.25
Resistance 1 (R1) 12.75 12.77 12.58 12.61 13.17
Pivot Point 12.40 12.40 12.32 12.34 12.40
Support 1 (S1) 11.79 12.04 11.62 11.65 11.09
Support 2 (S2) 11.44 11.81 11.38 11.01
Support 3 (S3) 10.83 11.44 10.93
Support 4 (S4) 10.69